@jill7517, Unfortunately, the research doesn't always keep up with our needs. I'm not an expert, I'm a patient with the ALK mutation. I'm waiting for research and studies to stay ahead of what I need to stay alive. It's not an easy position to be in; always watching and waiting for positive results, only to usually be disappointed as studies fail. But there are some bright lights and advances, and I hang my hopes on those studies and researchers.
For EGFR, the ADAURA study included some reference to 1B patients, but not 1A (https://www.nejm.org/doi/full/10.1056/NEJMoa2304594 ).
Even with a progressive oncologist, it can be difficult to get these drugs prescribed off-label, largely due to the high cost. (In the US), Sadly, it can be difficult to get insurance companies to cover the cost, and the drugs can often cost many tens of thousand dollars each month.
Have you thought of seeking a second opinion, possibly from an EGFR expert? They may be able to add reassurance or other thoughts.